Christopher G Schwarz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3097650/publications.pdf

Version: 2024-02-01

82547 57758 6,620 157 44 72 citations h-index g-index papers 160 160 160 7356 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Longitudinal tau PET in ageing and Alzheimer's disease. Brain, 2018, 141, 1517-1528.	7.6	309
2	Medical Image Synthesis for Data Augmentation and Anonymization Using Generative Adversarial Networks. Lecture Notes in Computer Science, 2018, , 1-11.	1.3	265
3	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. Neurolmage: Clinical, 2016, 11, 802-812.	2.7	249
4	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	7.4	223
5	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain, 2018, 141, 271-287.	7.6	218
6	Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology, 2010, 67, 1370.	4.5	216
7	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.	9.0	182
8	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	3.1	158
9	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. Neurolmage, 2014, 94, 65-78.	4.2	155
10	[¹⁸ F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	3.9	136
11	The evolution of primary progressive apraxia of speech. Brain, 2014, 137, 2783-2795.	7.6	134
12	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236.	2.4	133
13	The bivariate distribution of amyloid \hat{l}^2 and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
14	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	7.6	126
15	Identification of Anonymous MRI Research Participants with Face-Recognition Software. New England Journal of Medicine, 2019, 381, 1684-1686.	27.0	124
16	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.8	113
17	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	1.6	106
18	Episodic memory function is associated with multiple measures of white matter integrity in cognitive aging. Frontiers in Human Neuroscience, 2012, 6, 56.	2.0	100

#	Article	IF	CITATIONS
19	Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	2.4	86
20	Fully-Automated White Matter Hyperintensity Detection with Anatomical Prior Knowledge and without FLAIR. Lecture Notes in Computer Science, 2009, 21, 239-251.	1.3	84
21	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74
22	[¹⁸ F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	. 5.3	73
23	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	7.6	72
24	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	9.0	69
25	Entorhinal cortex tau, amyloid- \hat{l}^2 , cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	7.6	68
26	[¹⁸ F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	5. 3	67
27	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	7.6	67
28	Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiology of Aging, 2013, 34, 1996-2002.	3.1	66
29	\hat{I}^2 -Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.1	65
30	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. Neurolmage, 2021, 224, 117433.	4.2	63
31	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.1	62
32	\hat{l}^2 -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.1	62
33	White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimer's and Dementia, 2013, 9, S124-31.	0.8	61
34	In vivo ¹⁸ F-AV-1451 tau PET signal in <i>MAPT</i> mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.1	60
35	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	4.2	59
36	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	9.0	57

#	Article	IF	Citations
37	White matter hyperintensities correlate to cognition and fiber tract integrity in older adults with HIV. Journal of NeuroVirology, 2017, 23, 422-429.	2.1	55
38	Dissociable Effects of Alzheimer Disease and White Matter Hyperintensities on Brain Metabolism. JAMA Neurology, 2013, 70, 1039.	9.0	54
39	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. Neurolmage: Clinical, 2019, 23, 101823.	2.7	54
40	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	3.6	53
41	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	11.6	52
42	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. Brain, 2020, 143, 2281-2294.	7.6	51
43	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	2.2	49
44	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53.	1.6	49
45	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	5. 3	49
46	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	2.6	48
47	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. Neurolmage: Clinical, 2020, 25, 102152.	2.7	46
48	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	2.6	45
49	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. Cerebral Cortex, 2021, 31, 1693-1706.	2.9	44
50	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	2.4	42
51	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain, 2018, 141, 302-317.	7.6	42
52	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.8	41
53	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	2.0	39
54	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	3.3	38

#	Article	IF	Citations
55	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. Neurolmage, 2021, 231, 117845.	4.2	38
56	White Matter Reference Region in PET Studies of ¹¹ C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-I ² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	5.0	37
57	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	7.6	37
58	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.8	36
59	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	3.1	35
60	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	3.0	34
61	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	12.8	34
62	The value of resting-state functional MRI in subacute ischemic stroke: comparison with dynamic susceptibility contrast-enhanced perfusion MRI. Scientific Reports, 2017, 7, 41586.	3.3	33
63	[P2–415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.8	33
64	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	7.6	33
65	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	3.9	33
66	Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage Psychology and Aging, 2013, 28, 191-201.	1.6	32
67	Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	5.3	32
68	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1244-1250.	3.6	30
69	Pattern of regional white matter hyperintensity volume in mild cognitive impairment subtypes and associations with decline in daily functioning. Neurobiology of Aging, 2020, 86, 134-142.	3.1	30
70	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	3.0	30
71	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302.	2.7	30
72	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676.	1.6	29

#	Article	IF	Citations
73	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	2.7	29
74	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.1	28
75	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	2.6	27
76	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.1	27
77	Association of Initial \hat{l}^2 -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	9.0	27
78	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	2.7	27
79	Contributions of imprecision in <scp>PET</scp> â€ <scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp> <scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336.	3.6	26
80	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	1.5	26
81	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	7.6	26
82	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase, 2018, 24, 111-120.	0.6	25
83	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	3.4	25
84	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. Neurolmage, 2021, 238, 118259.	4.2	24
85	[ICâ€Pâ€122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. Alzheimer's and Dementia, 2017, 13, P93.	0.8	22
86	Association of Longitudinal \hat{l}^2 -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	5.9	22
87	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2020, 16, 1013-1022.	0.8	20
88	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	2.4	19
89	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	2.2	19
90	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.1	19

#	Article	IF	Citations
91	$^{\circ}$ sup>1 $^{\circ}$ 1 $^{\circ}$ H-MRS metabolites and rate of \hat{l}^2 -amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.1	18
92	Investigation of white matter PiB uptake as a marker of white matter integrity. Annals of Clinical and Translational Neurology, 2019, 6, 678-688.	3.7	18
93	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	3.1	18
94	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	5.3	17
95	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	3.7	17
96	Relationships between \hat{l}^2 -amyloid and tau in an elderly population: An accelerated failure time model. Neurolmage, 2021, 242, 118440.	4.2	15
97	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	3.3	15
98	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	3.1	14
99	\hat{l}^2 -Amyloid PET and $\langle \sup 123 \langle \sup \rangle$ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.1	13
100	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	2.0	13
101	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850.	2.7	13
102	Apolipoprotein ε4 Is Associated with Lower Brain Volume in Cognitively Normal Chinese but Not White Older Adults. PLoS ONE, 2015, 10, e0118338.	2.5	12
103	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. European Journal of Neurology, 2018, 25, 1352-1357.	3.3	12
104	Neural correlates of domain-specific cognitive decline. Neurology, 2019, 92, e1051-e1063.	1.1	12
105	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	3.6	12
106	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	3.3	12
107	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, .	1.1	12
108	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	3.1	11

#	Article	IF	Citations
109	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. Neurolmage: Clinical, 2022, 34, 102999.	2.7	11
110	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	3.9	11
111	Segment-Based Hand Pose Estimation. , 0, , .		10
112	Characterizing Topological Patterns in Amnestic Mild Cognitive Impairment by Quantitative Water Diffusivity. Journal of Alzheimer's Disease, 2014, 43, 687-697.	2.6	10
113	The influence of \hat{I}^2 -amyloid on [$<$ sup $>$ 18 $<$ /sup $>$ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.1	10
114	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. Scientific Reports, 2018, 8, 7421.	3.3	9
115	Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. Neurotherapeutics, 2021, 18, 661-672.	4.4	9
116	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. Neurolmage, 2022, 251, 119020.	4.2	9
117	Phonological Errors in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2021, 50, 195-203.	1.5	8
118	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12299.	2.4	8
119	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	2.2	7
120	Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	2.6	7
121	<i>APOE</i> $\hat{l}\mu$ 4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 784-796.	0.8	7
122	Face recognition from research brain PET: An unexpected PET problem. NeuroImage, 2022, 258, 119357.	4.2	6
123	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	2.4	5
124	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	2,4	5
125	Disrupted functional connectivity between perirhinal and parahippocampal cortices with hippocampal subfields in patients with mild cognitive impairment and Alzheimer's disease. Oncotarget, 2017, 8, 99112-99124.	1.8	5
126	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	3. 3	5

#	Article	IF	CITATIONS
127	Effects of T2-weighted MRI based cranial volume measurements on studies of the aging brain. Proceedings of SPIE, 2013, 8669, .	0.8	4
128	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	3.9	4
129	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.00000000000555.	1.6	4
130	CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200.	3.1	4
131	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268.	2.0	3
132	ICâ€Pâ€127: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR. Alzheimer and Dementia, 2019, 15, P104.	8.8	3
133	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	3.1	3
134	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	4.2	3
135	Left–Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. Journal of Magnetic Resonance Imaging, 2022, , .	3.4	3
136	The Camera-Driven Interactive Table. , 2007, , .		2
137	P3â€382: METHODS TO IMPROVE SPM12 TISSUE SEGMENTATIONS OF OLDER ADULT BRAINS. Alzheimer's and Dementia, 2018, 14, P1240.	0.8	2
138	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	2.4	2
139	Most edges in Markov random fields for white matter hyperintensity segmentation are worthless., 2012, 2684-7.		1
140	[P1–446]: EFFECTS OF USING A NOVEL LONGITUDINAL PROCESSING PIPELINE FOR MEASURING CHANGE OVER TIME IN PIBâ€PET. Alzheimer's and Dementia, 2017, 13, P455.	² 0.8	1
141	Diffusion Specific Segmentation: Skull Stripping with Diffusion MRI Data Alone. Mathematics and Visualization, 2018, , 67-80.	0.6	1
142	ICâ€Pâ€189: METHODS TO IMPROVE SPM12 TISSUE SEGMENTATIONS OF OLDER ADULT BRAINS. Alzheimer's and Dementia, 2018, 14, P157.	d _{0.8}	1
143	P2â€334: THE INFLUENCE OF BETAâ€AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH. Alzheimer's and Dementia, 2018, 14, P810.	0.8	1
144	Popular MRI deâ€facing software does not sufficiently protect participants from reâ€identification via face recognition. Alzheimer's and Dementia, 2020, 16, e045157.	0.8	1

#	Article	IF	CITATIONS
145	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	2.6	1
146	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	2.4	1
147	Impact of Markov Random Field optimizer on MRI-based tissue segmentation in the aging brain. , 2011, 2011, 7812-5.		O
148	P4-092: Optimizing PiB-PET change-over-time measurement by analysis of longitudinal reliability, plausibility, and separability., 2015, 11, P808-P809.		0
149	IC-04-04: Optimizing PiB-PET change-over-time measurement by analysis of longitudinal reliability, plausibility, and separability., 2015, 11, P11-P12.		O
150	[ICâ€Pâ€021]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€B BINDING IN WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P23.	0.8	0
151	[P3â€"343]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€B BINDING IN WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P1085.	0.8	O
152	[ICâ€Pâ€019]: EFFECTS OF USING A NOVEL LONGITUDINAL PROCESSING PIPELINE FOR MEASURING CHANGE OV TIME IN PIBâ€PET. Alzheimer's and Dementia, 2017, 13, P21.	'ER 0.8	0
153	[ICâ€Pâ€072]: AUTOMATED MEASUREMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P59.	0.8	O
154	[P1â€"380]: AUTOMATED MEASURMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P410.	0.8	0
155	Editorial for "Improving Spatial Normalization of Brain Diffusion MRI to Measure Longitudinal Changes of Tissue Microstructure in the Cortex and White Matter― Journal of Magnetic Resonance Imaging, 2020, 52, 776-777.	3.4	O
156	Optimizing software methods for measuring flortaucipir SUVR change over time. Alzheimer's and Dementia, 2021, 17, .	0.8	0
157	Dementia with Lewy bodies subtypes identified by cluster analysis on structural MRI. Alzheimer's and Dementia, 2021, 17, .	0.8	0